Benitec Biopharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BNTC research report →
Companybenitec.com
Benitec Biopharma Inc. , a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions.
- CEO
- Jerel A. Banks
- IPO
- 2014
- Employees
- 16
- HQ
- Hayward, CA, US
Price Chart
Valuation
- Market Cap
- $289.24M
- P/E
- -11.13
- P/S
- 520.22
- P/B
- 2.97
- EV/EBITDA
- -1.90
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 28.60%
- Op Margin
- -9701.08%
- Net Margin
- -8792.09%
- ROE
- -34.82%
- ROIC
- -29.28%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-37,917,000 · -74.32%
- EPS
- $-1.05 · 60.82%
- Op Income
- $-41,765,000
- FCF YoY
- -20.55%
Performance & Tape
- 52W High
- $17.15
- 52W Low
- $9.85
- 50D MA
- $11.85
- 200D MA
- $12.71
- Beta
- 0.28
- Avg Volume
- 143.59K
Get TickerSpark's AI analysis on BNTC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 22, 26 | Mates Sharon | other | 31,500 |
| Dec 29, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 65,800 |
| Dec 26, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 14,320 |
| Dec 23, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 42,600 |
| Dec 29, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 11,587 |
| Dec 26, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 2,516 |
| Dec 23, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 7,400 |
| Dec 22, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 16,650 |
| Dec 19, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 13,950 |
| Dec 18, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 8,700 |
Our BNTC Coverage
We haven't published any research on BNTC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BNTC Report →